Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial

What Was Tested

The paper reports a study of Tirzepatide, published as a randomized controlled trial.

Who Took Part

The study group was 2539 adults.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Blinding on both sides kept the adults and researchers unaware of who received Tirzepatide.

A placebo (an inactive look-alike) gave the Tirzepatide group a baseline to be compared against.

SUA was measured at baseline and multiple time points during the 72-week study across the 3 active trial arms, and changes were compared to the placebo arm.

The association between weight changes and SUA changes was evaluated by mediation analysis.

What Was Measured

Topics PubMed links to this paper include Uric Acid, Weight Loss, Obesity, Overweight, Tirzepatide, Body Mass Index and Anti-Obesity Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide in 2539 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Annals of the rheumatic diseases), a journal based in United States.

More context: the Tirzepatide compound page, all human trials.